Company Overview - Spectrum Brands (SPB) is expected to report a year-over-year decline in earnings, with a projected EPS of $1.35, reflecting a decrease of 16.7% compared to the previous year [3] - Revenues for the upcoming quarter are anticipated to be $694.91 million, down 3.3% from the same quarter last year [3] Earnings Expectations - The earnings report is scheduled for release on May 8, 2025, and the stock price may react positively if actual results exceed expectations [2] - Conversely, if the results fall short, the stock may decline [2] Estimate Revisions - The consensus EPS estimate has been revised down by 6.16% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Spectrum is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +3.70% [10][11] Historical Performance - In the last reported quarter, Spectrum had an earnings surprise of +12.09%, with actual earnings of $1.02 per share compared to an expected $0.91 [12] - Over the past four quarters, Spectrum has beaten consensus EPS estimates two times [13] Industry Context - Another company in the same industry, Central Garden (CENT), is expected to report earnings of $0.94 per share, reflecting a year-over-year decline of 5.1% [17] - Central Garden's revenues are projected to be $875.2 million, down 2.8% from the previous year [17]

Crocs (CROX) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on May 8, 2025, might help the stock move higher if these key numbers are better than expectations. ...

Core Viewpoint - Wave Life Sciences (WVE) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended March 2025, which could significantly influence its stock price based on actual results compared to estimates [1][2]. Company Summary - The consensus estimate indicates a quarterly loss of $0.27 per share for Wave Life Sciences, reflecting a year-over-year change of -12.5%. Revenues are projected to be $13.97 million, representing an 11.4% increase from the previous year [3]. - Over the last 30 days, the consensus EPS estimate has been revised 0.43% lower, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Wave Life Sciences is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.89%. The company currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat [10][11]. Earnings Surprise History - In the last reported quarter, Wave Life Sciences was expected to post a loss of $0.17 per share but instead reported earnings of $0.17, resulting in a surprise of +200%. However, the company has only beaten consensus EPS estimates once in the last four quarters [12][13]. Industry Context - Rhythm Pharmaceuticals, another company in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $0.69 per share for the same quarter, indicating a year-over-year change of +70.6%. Its revenues are expected to be $40.18 million, up 54.7% from the previous year [17]. - The consensus EPS estimate for Rhythm Pharmaceuticals has been revised 0.7% lower in the last 30 days, leading to an Earnings ESP of -12.84% and a Zacks Rank of 3, complicating predictions for an earnings beat [18].

Core Viewpoint - The market anticipates a year-over-year decline in Allbirds, Inc. (BIRD) earnings due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Allbirds is expected to report a quarterly loss of $3.85 per share, reflecting a -6.9% change year-over-year [3]. - Revenue is projected to be $30.87 million, down 21.5% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.67% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate is lower than the Zacks Consensus Estimate, leading to an Earnings ESP of -1.04%, suggesting a bearish outlook [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict earnings deviation, but its predictive power is significant mainly for positive readings [7][8]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically shown a nearly 70% chance of a positive surprise [8]. Historical Performance - In the last reported quarter, Allbirds was expected to post a loss of $3.52 per share but delivered a loss of $3.23, resulting in a surprise of +8.24% [12]. - Over the past four quarters, Allbirds has beaten consensus EPS estimates four times [13]. Conclusion - Allbirds does not appear to be a compelling earnings-beat candidate, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [16].

Core Viewpoint - The market anticipates that Dave Inc. (DAVE) will report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended March 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate for DAVE's quarterly earnings is $1.54 per share, reflecting a year-over-year increase of +148.4%. Revenues are projected to be $91.6 million, which is a 24.5% increase from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 22.22%, indicating a collective reassessment by analysts regarding the company's earnings prospects [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for DAVE is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -34.85%, suggesting a bearish outlook from analysts [10][11]. Historical Performance - In the last reported quarter, DAVE was expected to post earnings of $1.09 per share but exceeded expectations with earnings of $2.04, achieving a surprise of +87.16%. Over the past four quarters, the company has beaten consensus EPS estimates three times [12][13]. Investment Considerations - Despite a strong Zacks Rank of 1, the negative Earnings ESP reading complicates the prediction of an earnings beat for DAVE. Investors are advised to consider other factors beyond earnings surprises when making investment decisions [11][16].

Core Viewpoint - The market anticipates a significant year-over-year decline in earnings for Canadian Solar, with a consensus estimate of a quarterly loss of $1.50 per share and revenues expected to drop by 18.1% to $1.09 billion [3][4]. Company Summary - Canadian Solar is projected to report a quarterly loss of $1.50 per share, reflecting a drastic year-over-year change of -889.5% [3]. - The expected revenue for the quarter is $1.09 billion, which is an 18.1% decrease compared to the same quarter last year [3]. - The consensus EPS estimate has been revised down by 164.29% over the last 30 days, indicating a significant reassessment by analysts [4]. - The Most Accurate Estimate for Canadian Solar is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +13.81% [10][11]. - Despite the positive Earnings ESP, the stock carries a Zacks Rank of 5, complicating predictions of an earnings beat [11]. Industry Summary - SolarEdge Technologies, a competitor in the solar industry, is expected to report earnings per share of $1.20 for the same quarter, indicating a year-over-year increase of +36.8% [17]. - SolarEdge's revenues are projected to be $203.8 million, reflecting a slight decrease of 0.3% from the previous year [17]. - The consensus EPS estimate for SolarEdge has been revised down by 2.5% over the last 30 days, resulting in an Earnings ESP of -8.73% [18].

Core Viewpoint - Ironwood Pharmaceuticals (IRWD) is anticipated to report a year-over-year decline in earnings due to lower revenues for the quarter ended March 2025, with the consensus outlook indicating a significant impact on its near-term stock price [1][3]. Earnings Expectations - The consensus EPS estimate for Ironwood is a loss of $0.05 per share, reflecting a year-over-year change of -150% [3]. - Expected revenues are projected at $59.45 million, which is a decrease of 20.6% compared to the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 42.86%, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Ironwood is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -121.05% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictive power for positive readings [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically produced a positive surprise nearly 70% of the time [8]. Historical Performance - Ironwood has not been able to beat consensus EPS estimates in any of the last four quarters, with a notable surprise of -80% in the last reported quarter [12][13]. Conclusion - Ironwood does not appear to be a compelling candidate for an earnings beat, and investors should consider other factors when making decisions regarding this stock ahead of its earnings release [16].

Core Viewpoint - Ford is expected to report breakeven EPS and automotive revenues of $35.5 billion for Q1 2025, reflecting an 11% decline from the previous year [1][3]. Financial Estimates - The Zacks Consensus Estimate for Ford's full-year automotive revenues in 2025 is $162.3 billion, indicating a 6% year-over-year decline [3]. - The consensus estimate for full-year EPS is $1.22, representing a 33.7% contraction compared to the previous year [3]. - In the trailing four quarters, Ford surpassed EPS estimates twice, missed once, and matched once, with an average earnings surprise of 1.21% [3]. Sales Performance - Ford's sales volume for Q1 2025 is projected to decline by 1.3% to 501,291 units, attributed to rental fleet sales timing and the discontinuation of certain models [5]. - Retail sales increased by 5% during the quarter, while sales of electrified vehicles surged by 25.5% to 73,623 units [5]. Segment Revenue Estimates - The Zacks Consensus Estimate for revenues from the Ford Blue unit is $17.6 billion, down 19% year-over-year, with EBIT expected to drop from $905 million to $275 million [8]. - Revenues from the Ford model e unit are estimated at $1.5 billion, a significant increase from $115 million in the same period last year, with a projected loss before interest and taxes of $1.17 billion [9]. - The Ford Pro unit's revenues are expected to be $16.2 billion, reflecting a 10% decline year-over-year, with EBIT anticipated to decrease from $3 billion to $1.5 billion [10]. Market Performance - Year-to-date, Ford's shares have increased by 1.1%, outperforming both Tesla and General Motors, whose shares have dropped by 30% and 15%, respectively [11]. - Ford is trading at a forward price/sales ratio of 0.24, significantly lower than the industry average of 2.37, indicating a relatively cheap valuation [14]. Future Outlook - Ford's 2025 outlook is cautious, with full-year adjusted EBIT forecasted at $7-$8.5 billion, down from $10.2 billion in 2024, influenced by warranty costs and incentives [18]. - Despite challenges, the Ford Pro segment is expected to be a major profit driver, supported by strong order books and demand signals [19]. - Ford maintains a high dividend yield of approximately 6%, targeting a payout ratio of 40-50% of free cash flow, which is attractive to income-focused investors [19].

Core Insights - Wall Street analysts expect Zoetis (ZTS) to report quarterly earnings of $1.40 per share, reflecting a year-over-year increase of 1.5% [1] - Revenues are anticipated to be $2.19 billion, unchanged from the same quarter last year [1] - The consensus EPS estimate has been revised 0.2% lower over the last 30 days, indicating a reevaluation of initial estimates by analysts [1] Revenue Estimates - 'Revenues- Contract Manufacturing & Human Health' are projected to reach $19.16 million, a decrease of 4.2% from the prior-year quarter [4] - 'Revenues- Companion Animal' are expected to be $1.54 billion, showing an increase of 6.3% year over year [4] - 'Revenues- Livestock' are estimated at $631.41 million, indicating a decline of 12.3% compared to the previous year [4] Livestock Revenue Breakdown - 'Revenues- Livestock - Cattle' are forecasted at $324.74 million, reflecting a decrease of 17% from the prior-year quarter [5] - 'Revenues- Livestock - Swine' are expected to reach $128.40 million, suggesting a slight increase of 1.1% year over year [5] - 'Revenues- Livestock - Poultry' are projected to be $142.19 million, indicating a year-over-year increase of 2.3% [5] Geographic Revenue Estimates - 'Geographic Revenues- U.S.' are estimated at $1.19 billion, reflecting a year-over-year increase of 2% [6] - 'Geographic Revenues- International Revenue' are expected to be $987.35 million, indicating a decrease of 2% year over year [6] - 'Geographic Revenues- International - Livestock' are projected at $402.51 million, reflecting a decline of 11.5% from the prior-year quarter [6] Companion Animal Revenue Insights - 'Geographic Revenues- International - Companion Animal' are expected to reach $587.13 million, indicating a year-over-year increase of 6.4% [7] - 'Geographic Revenues- U.S.- Livestock' are projected at $225.66 million, suggesting a decrease of 14.8% year over year [7] - 'Geographic Revenues- U.S.- Companion Animal' are estimated at $955.61 million, reflecting a year-over-year increase of 6.4% [8] Stock Performance - Shares of Zoetis have decreased by 4.3% in the past month, compared to a 0.7% decline in the Zacks S&P 500 composite [8] - With a Zacks Rank 3 (Hold), Zoetis is expected to mirror the overall market performance in the near future [8]

Core Insights - Westlake Chemical (WLK) is expected to report quarterly earnings of $0.70 per share, a decline of 47.8% year-over-year, with revenues forecasted at $2.92 billion, reflecting a decrease of 1.9% compared to the same period last year [1] Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been revised downward by 9.8%, indicating a reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3] Key Metrics Projections - The consensus estimate for 'Net external sales- Performance and Essential Materials' is $1.91 billion, down 1.1% year-over-year [5] - Analysts predict 'Net external sales- Housing and Infrastructure Products' will reach $1.06 billion, reflecting a year-over-year increase of 2% [5] - 'Net external sales- Performance and Essential Materials- Performance Materials' is estimated at $1.12 billion, a decrease of 3.4% year-over-year [6] - 'Net external sales- Performance and Essential Materials- Essential Materials' is projected at $753.23 million, down 1.8% year-over-year [6] - 'Net external sales- Housing and Infrastructure Products- Housing Products' is expected to be $883.99 million, a slight increase of 0.6% year-over-year [7] - 'Net external sales- Housing and Infrastructure Products- Infrastructure Products' is estimated at $172.19 million, reflecting a year-over-year increase of 4.4% [7] EBITDA Estimates - Analysts estimate 'EBITDA- Housing and Infrastructure Products' at $231.71 million, down from $264 million in the same quarter last year [8] - 'EBITDA- Performance and Essential Materials' is projected to be $199.94 million, compared to $253 million in the previous year [8] Stock Performance - Over the past month, shares of Westlake have declined by 9.4%, while the Zacks S&P 500 composite has decreased by only 0.7% [9] - Westlake currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance relative to the overall market in the near future [9]